Sol-Gel Technologies (SLGL) Other Non-Current Assets (2017 - 2026)
Sol-Gel Technologies (SLGL) reported Other Non-Current Assets of $396000.0 for Q1 2026, up 29.84% year-over-year from $305000.0 in Q1 2025, and up 538.71% quarter-over-quarter from $62000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Other Non-Current Assets data on file, last reported at $396000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $396000.0, up 29.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $396000.0 (up 29.84% YoY), and the FY2025 annual result was $62000.0, down 99.7% from the prior year.
- Other Non-Current Assets climbed to $396000.0 in Q1 2026 per SLGL's latest filing, from $62000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.5 million in Q3 2024 and troughed at $45000.0 in Q1 2024.
- A 5-year average of $737411.8 and a median of $729000.0 in 2023 frame the typical range for Other Non-Current Assets.
- On a YoY basis, Other Non-Current Assets climbed as much as 577.78% in 2025 and fell as far as 94.73% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $1.2 million in 2022, then slumped by 69.57% to $350000.0 in 2023, then surged by 236.0% to $1.2 million in 2024, then plunged by 94.73% to $62000.0 in 2025, then jumped by 538.71% to $396000.0 in 2026.
- Business Quant data shows SLGL's Other Non-Current Assets at $396000.0 in Q1 2026, $62000.0 in Q4 2025, and $352000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 396,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 396,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 305,000.00 |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 45,000.00 |
| Dec 31, 2023 | 350,000.00 |
| Sep 30, 2023 | 680,000.00 |
| Jun 30, 2023 | 712,000.00 |
| Mar 31, 2023 | 729,000.00 |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 730,000.00 |
| Jun 30, 2022 | 1.15 Mn |
| Mar 31, 2022 | 814,000.00 |
| Dec 31, 2021 | 1.15 Mn |
| Sep 30, 2021 | 752,000.00 |
| Jun 30, 2021 | 744,000.00 |